These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37516019)

  • 1. From bench to bedside: The promise of sotatercept in hematologic disorders.
    Lan Z; Lv Z; Zuo W; Xiao Y
    Biomed Pharmacother; 2023 Sep; 165():115239. PubMed ID: 37516019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
    Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O
    Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
    Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
    Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
    Fenaux P; Kiladjian JJ; Platzbecker U
    Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activin receptor antagonists for cancer-related anemia and bone disease.
    Fields SZ; Parshad S; Anne M; Raftopoulos H; Alexander MJ; Sherman ML; Laadem A; Sung V; Terpos E
    Expert Opin Investig Drugs; 2013 Jan; 22(1):87-101. PubMed ID: 23127248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
    Raje N; Vallet S
    Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration.
    Rochette L; Zeller M; Cottin Y; Vergely C
    Pharmacol Ther; 2015 Dec; 156():26-33. PubMed ID: 26523637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of activin receptor type IIA and IIB-Fc fusion proteins by automated capillary immunoassay.
    Desharnais P; Naud JF
    Drug Test Anal; 2022 Nov; 14(11-12):1938-1951. PubMed ID: 36200177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway.
    De Rosa G; Andolfo I; Marra R; Manna F; Rosato BE; Iolascon A; Russo R
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated, sensitive electrophoretic method for the detection of activin receptor type II-Fc fusion proteins in human blood.
    Martin L; Zouhiri N; Audran M; Marchand A
    Drug Test Anal; 2018 Mar; ():. PubMed ID: 29499588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
    Raftopoulos H; Laadem A; Hesketh PJ; Goldschmidt J; Gabrail N; Osborne C; Ali M; Sherman ML; Wang D; Glaspy JA; Puccio-Pick M; Zou J; Crawford J
    Support Care Cancer; 2016 Apr; 24(4):1517-25. PubMed ID: 26370220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.
    Aykul S; Martinez-Hackert E
    J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel activin-targeted therapeutics.
    Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
    Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.